Turn Therapeutics, Inc. focuses on solving massive health problems by eliminating diseases and strengthening health systems through powerful partnerships and operational research. The company is headquartered in Westlake Village, California. The company went IPO on 2025-10-08. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción TTRX?
El precio actual de TTRX es de $5.06, ha increased un 0.79% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Turn Therapeutics Inc?
Turn Therapeutics Inc pertenece a la industria N/A y el sector es N/A
¿Cuál es la capitalización bursátil de Turn Therapeutics Inc?
La capitalización bursátil actual de Turn Therapeutics Inc es $141.7M
